Label-free array techniques eliminate the use of heavy florescent and other labels for the detection of new molecules. Label-free array techniques have various advantages over traditional labelled techniques, such as fast delivery, reliability, and robust & accurate results in real time. Label-free array techniques do not use any radioactive or fluorescent labels, tags, dyes, or any specialized reagent for the preparation of assays, which reduces overall cost of the technique.
Transparency Market Research (TMR) has published a new report on the label-free array systems market for the forecast period of 2019–2027. According to the report, the global label-free array systems market was valued at ~ US$ 1.1 Bn in 2018, and is projected to expand at a CAGR of ~ 7% from 2019 to 2027.
Surface Plasmon Resonance to be Highly Attractive
The report offers detailed segmentation of the global label-free array systems market based on technique, application, and end user. In terms of technique, the surface plasmon resonance segment is poised to account for a prominent share of the global label-free array systems market during the forecast period, due to the increase in application of SPR in drug discovery, kinetic analysis, and antigen antibody reaction in protein microarrays. Moreover, various advantages of SPR technology such as real-time monitoring, ability to replicate the results, and ease of assay preparation are boosting the growth of the segment in the label-free array systems market.
Request Sample of the Report:
North America to Create High Incremental Opportunity
In terms of revenue, North America is projected to be a prominent region in the global label-free array systems market from 2019 to 2027. This can be ascribed to the early adoption of technologically-advanced label-free array systems in the U.S. and Canada. The presence of leading market players, their growing investments in research, and FDA approvals for the commercial launch of label-free array systems boost the growth of the label-free array systems market in North America.
Pharmaceutical and Biotechnology Industries Offer Huge Opportunities
Increase in R&D spending by pharmaceutical and biotech companies is one of the factors driving the global label-free array systems market. A large number of companies focus on new and targeted drug development to gain a competitive edge in the highly fragmented industry. Growth of the pharmaceutical and biotechnology industries segment can be attributed to the patent expiry of drugs, which is putting the pharmaceutical industry under intense pressure, with R&D costs continuing to rise, but the number of drug discoveries remaining static.
Request Broucher of the Report: